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jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/ jcc as eStent implantation has been used to treat coronary artery
stenosis for about three decades. Treatment with bare metal stent
(BMS) successfully restores the acute vessel lumen, but the long-
term outcomes are often compromised by in-stent restenosis (ISR).
Use of drug-eluting stents (DES) has signiﬁcantly reduced ISR
compared with BMS over mid-term follow-up [1]. However, recent
studies have shown that DES are associated with delayed and
progressive neointimal proliferation during long-term follow-up,
termed the ‘‘late catch-up’’ phenomenon [2]. One of the established
mechanisms underlying late or very late ISR in DES is neoathero-
sclerosis developing within neointima. Neoatherosclerosis is
pathohistologically recognized as clusters of lipid pools within
the neointima, representing the entire spectrum from lipid-rich
plaque to plaque rupture.
In contrast to late or very late ISR, histopathological evaluation
of early-phase (within 12 months after stent implantation) ISR
lesions in DES has not been systematically conducted due to
insufﬁcient availability of autopsy samples. The availability of
optical coherence tomography (OCT) has enabled us to identify the
morphological characteristics of neointimal tissue (homogeneous,
layered, or heterogeneous patterns) in vivo [3]. Early-phase ISR
lesions in DES are more often hypocellular heterogeneous tissue
comprising scanty smooth muscle cells and abundant extracellular
matrix such as proteoglycan and ﬁbrin [4]. A comparison of OCT
ﬁndings and histopathological ﬁndings of retrieved restenotic
tissue demonstrated that layered or heterogeneous intima without
attenuation on OCT images may represent extracellular matrix or
ﬁbrin accumulation [5]. The neointimal healing process was
materialized by the substitution of smooth muscle cells for ﬁbrin
deposition after stent implantation [6]. DES delays this neointimal
healing process, and neointima with ﬁbrin accumulation (so-called
ﬁbrin thrombus) shows a heterogeneous OCT pattern in early-
phase ISR lesions in DES [7]. In addition, serial OCT examinations
9–18 months after DES implantation have shown that heteroge-
neous tissue composition detected at 9 months might be
associated with late neointimal tissue growth at 18 months [8].DOI of original article: http://dx.doi.org/10.1016/j.jccase.2015.06.004
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contributing to early-phase ISR, particularly with BMS [9]. On the
other hand, the main cause of early-phase ISR in DES remains
unclear. In this issue of the Journal of Cardiology Cases, Ito et al.
report a case of coronary angioscopic imaging of early-phase ISR
after biolimus-eluting coronary stent implantation [10]. Coronary
angioscopy is an endoscopic technology allowing direct visualiza-
tion of the surface color and superﬁcial morphology of ISR lesions.
Based on the heterogeneous pattern of OCT images, and the white
paste-like appearance on coronary angioscopy, the authors
speculated that ﬁbrin thrombus formation based on delayed
vascular healing process after DES implantation represented the
pathological cause in this case. DES strongly inhibits neointimal
growth by pharmacologically suppressing smooth muscle cell
proliferation and extracellular matrix production. Thus, DES delays
endothelial cell coverage of stent struts. Even after re-endothe-
lialization, endothelial function could be impaired after DES
implantation [11]. Endothelial dysfunction after DES implantation
may be related to excessive ﬁbrin thrombi causing coronary ﬂow
disturbance and the development of early-phase ISR. In addition,
this case has a history of type 2 diabetes mellitus (DM) [12]. In
general, DM is a well-known independent risk factor for ISR
[12]. Patients with DM have more complex coronary lesion
morphology, and higher plaque volume that may cause incomplete
and asymmetric stent expansion. Furthermore, patients with DM
often have systemic prothrombotic conditions related to the
activation of the platelet aggregation and coagulation systems
[13]. Resistance to both aspirin and clopidogrel occurs more
commonly in patients with DM compared to patients without DM
[14]. Considering the above-mentioned factors, not only local
factors but systemic factors also may contribute to the develop-
ment of early-phase ISR of DES with thrombus formation.
Despite ISR being markedly reduced by DES, a 5–7% incidence of
early-phase ISR lesions has been reported with DES in trials and
registries of percutaneous coronary intervention [15]. The ﬁndings
from this case report need to be further conﬁrmed, but this report
provides invaluable observations of early-phase ISR lesions in DES.
A clinical approach with multimodal coronary imaging, such as
intravascular ultrasound, OCT, and coronary angioscopy, coulds reserved.
Editorial / Journal of Cardiology Cases 12 (2015) 150–151 151reveal the underlying mechanisms of early-phase ISR in DES and
overcome the remaining problems after DES implantation.
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